Skip to main content

Table 2 Clinical features of ACLF patients based on different outcomes

From: The different expression of caspase-1 in HBV-related liver disease and acts as a biomarker for acute-on-chronic liver failure

Parameters Survivors (n = 30) Non-survivors (n = 41) P value
Age (years) 43.08 ± 9.7 46.10 ± 11.3 0.131
Gender (male/female) 18/12 26/15 0.293
Alanine aminotransferase (U/L) 444.9 ± 58.3 490.3 ± 66.2 0.614
Aspartate aminotransferase (U/L) 501.3 ± 87.6 536.1 ± 74.6 0.592
Total bilirubin (μmol/l) 332.8 ± 100.3 396.112 ± 87.3 0.007
Albumin (g/L) 32.56 ± 5.4 30.9 ± 4.11 0.009
HBsAg positive (n) 30 41
HBV DNA (log10 copies/mL) 4.44 ± 1.25 4.16 ± 1.62 0.024
Creatinine (μmol/L) 70.63 ± 26.9 79.65 ± 37.6 0.011
Prothrombin time (s) 24.1 ± 6.6 26.4 ± 9.8 0.044
International normalized ratio 2.31 ± 0.57 2.77 ± 0.55 0.056
IL-1β(pg/ml) 1.49 ± 0.63 1.57 ± 0.87 0.78
IL-18(pg/m) 287.33 ± 85.9 355.27 ± 100.14 0.007
  1. Abbreviations: ACLF acute-on-chronic liver failure, IL-1β, interleukin-1β, IL-18, interleukin-8